Company BioSenic SA

BIOS

BE0974280126

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 11:35:23 2024-04-19 am EDT			5-day change	1st Jan Change
0.0196 ^EUR	-3.92%		-15.15%	-67.97%

Apr. 11	Biosenic: launch of a debt restructuring plan	CF
Mar. 12	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

BioSenic SA is a leading biotech company specializing in the development of clinical assets issued from the allogeneic cell therapy platform ALLOB and from the Arsenic TriOxide (ATO) platform. Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures.

Following the merger in October 2022, BioSenic SA combines the strategic positionings and strengths of Medsenic and Bone Therapeutics.

The merger also enables Biosenic SA to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO.

Managers	Title	Age	Since
Francois Rieger CEO	Chief Executive Officer	-	-
Lieven Huysse CTO	Chief Tech/Sci/R&D Officer	-	23-04-02
Nicco Carole COO	Chief Operating Officer	-	23-01-17
Véronique Pomi-Schneiter BRD	Director/Board Member	-	-

Members of the board	Title	Age	Since
Jean-François Rax BRD	Director/Board Member	-	-
Jean-Luc Vandebroek BRD	Director/Board Member	53	-
Francois Rieger CEO	Chief Executive Officer	-	-
Yves Sagot BRD	Director/Board Member	60	23-01-26
Jean Stephenne BRD	Director/Board Member	75	-
Véronique Pomi-Schneiter BRD	Director/Board Member	-	-
Revital Rattenbach BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	192,873,548	141,530,236 ( 73.38 %)	0	73.38 %

Name	Equities	%	Valuation
OP Asset Management Ltd. 0.0552 %	106,440	0.0552 %	2 529 €
Tocqueville Finance SA 0.0273 %	52,596	0.0273 %	1 250 €
FundQuest Advisor 0.0222 %	42,897	0.0222 %	1 019 €
Puilaetco Dewaay Private Bankers SA 0.0162 %	31,267	0.0162 %	743 €
FV Frankfurter Vermögen AG 0.0104 %	20,000	0.0104 %	475 €
Allianz Global Investors GmbH (France) 0.000078 %	150	0.000078 %	4 €

BioSenic SA

Bâtiment H bte 24 Rue Granbonpré 11

1435, Mont-Saint-Guibert

+32 49 309 73 66

http://www.biosenic.com

Name	Category and Sector
Skeletal Cell Therapy Support SA Skeletal Cell Therapy Support SA Pharmaceuticals: MajorHealth Technology Skeletal Cell Therapy Support SA operates a pharmaceutical products manufacturing facility. The company is headquartered in Charleroi, Belgium.	Pharmaceuticals: Major

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.0196 EUR

Average target price

0.1 EUR

Spread / Average Target

+410.20%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
BIOSENIC SA	-67.97%	3.99M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals